Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset BEAM

Coverage 166,503 Raw stories ingested 21,889 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,349 ETH 4,859 XRP 3,278 SOL 2,984 HYPE 1,761 USDC 1,589

Stocks NVDA 1,790 SPCX 1,455 MU 1,325 MSFT 1,296 AAPL 1,042 TSLA 1,026

Commodities GOLD 549 SILVER 294 OIL 101 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 499 GBPUSD 378 USDCAD 150 USDJPY 146 AUDUSD 99 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 39s ago
FMP Forex News Fetch every 5 min 4m ago
CoinGecko News Fetch every 5 min 1m ago
FIO Stock News Fetch every 10 min 9m ago
Patria Stock News Fetch every 10 min 9m ago
Editorial rewrite Rewrite every minute 39s ago
Asset sync Assets every 1 hour 28m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-09-08 15:15 1d ago Published 2026-09-08 09:22 1d ago	Beam Therapeutics usiluje o zrychlené schválení BEAM-302 Beam Therapeutics oznámila, že po jednáních s FDA chce pro BEAM-302, terapii pro AATD, usilovat o zrychlené schválení. Data z 29 pacientů ukázala přijatelnou bezpečnost a silné biomarkerové výsledky. BEAM Beam Therapeutics	FMP Stock News	86
Original source text Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease. The company shared these findings at the European Respiratory Society Congress 2026, showcasing the genetic medicine’s potential to directly correct the root cause of both liver and lung complications associated with the disease. Promising Efficacy and Safety ProfileThe clinical trial evaluated single doses of BEAM-302 across two groups: Part A for patients with AATD-related lung disease and Part B for those with mild to severe liver disease. As of the June 2026 data cutoff, results from 29 patients demonstrated an acceptable safety profile. The most frequent side effects were mild-to-moderate infusion-related reactions, affecting 41% of participants. Read Next Researchers also observed mostly mild, temporary liver enzyme elevations. Patients receiving a 60 mg dose achieved sustained, functional alpha-1 antitrypsin (AAT) levels well above the protective 11 µM threshold. The therapy also reduced human neutrophil elastase activity and cut mutant Z-AAT proteins by 84% in both cohorts. Additionally, BEAM-302 decreased toxic protein aggregates known to worsen liver disease and amplify lung inflammation. After treatment, newly produced, corrected M-AAT made up 93% of circulating AAT, exceeding the levels typically seen in genetic carriers. Path To Accelerated ApprovalFollowing discussions with the U.S. Food and Drug Administration (FDA), Beam plans to pursue an accelerated approval pathway for the therapy. The submission will evaluate AAT biomarkers over a 12-month period using the 60 mg dose as the primary endpoint. To support a future biologics license application, the biotechnology firm anticipates enrolling roughly 50 additional patients with AATD-associated lung disease into an expansion of the ongoing trial. Beam initiated dosing for this pivotal global cohort in July. BEAM Stock Price Activity: Beam Therapeutics shares were down 7.17% at $27.53 during premarket trading on Tuesday, according to Benzinga Pro data. Image via Shutterstock Read Next Market News and Data brought to you by Benzinga APIs © 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. To add Benzinga News as your preferred source on Google, click here.
	Saved 2026-09-01 11:21 8d ago Published 2026-09-01 07:00 8d ago	Beam Therapeutics jmenovala Erica Fostera ředitelem pro komerční záležitosti Beam Therapeutics jmenovala Erica Fostera ředitelem pro komerční záležitosti. Povede komerční strategii firmy při přípravě možného uvedení risto-cel v roce 2027. BEAM Beam Therapeutics	FMP Stock News	78
Original source text \| Source: Beam Therapeutics CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. “Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets,” said John Evans, chief executive officer of Beam Therapeutics. “His decades of commercial leadership are impressive, including spearheading the commercial success of multiple blockbuster rare disease franchises at Horizon Therapeutics during a period of significant growth prior to its acquisition by Amgen. As we prepare for the potential launch of risto-cel in 2027, Eric's experience building strong teams and culture, defining and executing clear commercial strategies, and leading through growth will be invaluable as we lay the foundation for Beam's next chapter and work to bring multiple precision genetic medicines to patients in the years ahead.” Mr. Foster brings more than 25 years of commercial leadership experience across biotechnology and specialty pharmaceuticals and most recently served as chief commercial officer at Ardelyx. Prior to Ardelyx, Mr. Foster served as senior vice president and U.S. general manager at Amgen following the acquisition of Horizon Therapeutics in October 2023. At Horizon, he was senior vice president and general manager of the gout and ophthalmology business units, where he led operations for franchises that represented $2.75 billion in net sales revenue. Prior to his time at Horizon, from 2010 to 2021, Mr. Foster held roles of increasing responsibility in sales and marketing at GlaxoSmithKline across a variety of immunology and rare disease products, including serving as vice president of immunology marketing, senior global marketing director and field sales vice president. Mr. Foster began his career in sales and market access at Johnson & Johnson. Mr. Foster holds a Bachelor of Arts in Economics from the University of Georgia and a Master of Business Administration from Auburn University. “I'm excited to join Beam at such an important moment in the company's evolution,” said Foster. “Beam has built one of the most innovative platforms and deepest pipelines in biotechnology, with the potential to redefine how serious genetic diseases are treated. I look forward to partnering with the talented team at Beam to build a leading commercial organization, establish the capabilities needed to support multiple potential launches and, ultimately, bring these transformative medicines to patients.” About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the timing and effective date of the appointment of Mr. Foster; the contributions Mr. Foster may make in his role with the company; the therapeutic applications and potential of our technology; the anticipated timing of potential product launches, including any potential launch of risto-cel; our plans to advance our programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; our ability to build and scale commercial infrastructure, including a sales and marketing organization, to support potential product launches; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Contacts: Investors: Holly Manning Beam Therapeutics [email protected] Media: Josie Butler 1AB [email protected]
	Saved 2026-08-04 14:15 1mo ago Published 2026-08-04 09:26 1mo ago	Beam Therapeutics hlásí vyšší ztrátu a slabé tržby Beam Therapeutics vykázala ve 2. čtvrtletí ztrátu 1,18 USD na akcii a tržby 0,49 mil. USD, obojí výrazně pod odhady. BEAM Beam Therapeutics	FMP Stock News	78
Original source text Beam Therapeutics Inc. (BEAM - Free Report) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -18.00%. A quarter ago, it was expected that this company would post a loss of $0.87 per share when it actually produced a loss of $0.91, delivering a surprise of -4.6%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Beam Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.49 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 98.38%. This compares to year-ago revenues of $8.47 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Beam Therapeutics shares have lost about 6.5% since the beginning of the year versus the S&P 500's gain of 11%. What's Next for Beam Therapeutics?While Beam Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Beam Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.05 on $30.33 million in revenues for the coming quarter and -$4.16 on $122.7 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, EyePoint (EYPT - Free Report) , is yet to report results for the quarter ended June 2026. This drug delivery technology company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of -8.2%. The consensus EPS estimate for the quarter has been revised 8.9% lower over the last 30 days to the current level. EyePoint's revenues are expected to be $0.25 million, down 95.3% from the year-ago quarter.
	Saved 2026-08-04 11:51 1mo ago Published 2026-08-04 07:00 1mo ago	Beam Therapeutics podala první dávku v BEAM-302 Beam Therapeutics oznámila podání první dávky pacientovi v globální pivotní kohortě probíhající studie BEAM-302 pro AATD. Firma zároveň uvedla, že má 1,2 miliardy USD v hotovosti a cenných papírech. BEAM Beam Therapeutics	FMP Stock News	92
Original source text August 04, 2026 07:00 ET \| Source: Beam Therapeutics Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU) Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises. “The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam,” said John Evans, chief executive officer of Beam Therapeutics. “Importantly, this progress enabled dosing of the first patient in the global pivotal cohort evaluating BEAM-302, the most advanced genetic medicine in development for AATD, which has the potential to fundamentally change the treatment paradigm for patients. In addition, we completed dosing for all adult and adolescent SCD patients in the BEACON trial of risto-cel and received FDA clearance of the IND for BEAM-304 in PKU, paving the way to the clinic for this next potentially high-value franchise. Looking ahead, we believe Beam is positioned to achieve several important milestones, including updated clinical data for BEAM-302 at the ERS Congress, rapid enrollment in the BEAM-302 pivotal cohort, first-in-human data for BEAM-301 in GSDIa, and the expected BLA submission for risto-cel. With the continued expansion and advancement of our base editing pipeline, we have the potential to deliver transformative therapies for many patients with serious genetic diseases.” Second Quarter 2026 and Recent Progress and Anticipated Milestones Liver-targeted Genetic Disease Franchise BEAM-302: Beam’s lead genetic disease program is designed to be a best-in-class and first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and therefore has the potential to address both liver and lung manifestations of AATD. In July, Beam dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease. The cohort is designed to support a potential accelerated approval path in the United States.Detailed and updated clinical data for BEAM-302 were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, taking place September 5-9, 2026, in Barcelona, Spain. BEAM-304: BEAM-304 is designed to leverage Beam’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using an innovative platform approach with the goal of creating mutation-specific base editors for the majority of patients with PKU. In June, Beam announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for BEAM-304.Beam has initiated clinical start-up activities for the planned Phase 1/2 trial for BEAM-304. The trial will initially evaluate safety, tolerability, and reduction of blood Phe levels in PKU patients with the R408W mutation, one of the most prevalent disease-causing mutations among patients with PKU in the U.S., with a goal of establishing clinical proof of concept for base editing in PKU. The trial will subsequently evaluate base editors for additional mutations within a single clinical program.In July, updated preclinical data for BEAM-304 were presented at the Federation of American Societies for Experimental Biology (FASEB) Genome Engineering: Research and Applications Conference. The presentation is available on the Presentation and Publications page of Beam’s website beamtx.com. BEAM-301: BEAM-301 aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa). BEAM-301 is currently being evaluated in an open-label Phase 1/2 dose-exploration trial in patients with GSDIa.Beam expects to report initial clinical data in 2026. Hematology Franchise Risto-cel: Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of sickle cell disease (SCD). Dosing is complete in all adult and adolescent patients enrolled in the Phase 1/2 BEACON trial.Beam expects to report updated data for the BEACON trial by year-end 2026 and submit a biologics license application (BLA) for risto-cel as early as year-end 2026. Next-generation Programs in Sickle Cell Disease and Hematology: Beam completed enrollment and dosing in the Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody with the potential to enable non-genotoxic ex vivo and in vivo therapies for SCD. Treatment with BEAM-103 was well tolerated across all doses tested.Beam continues to make significant investments in developing targeted LNPs to deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC delivery have been identified and are in lead optimization. Second Quarter 2026 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $1.2 billion as of June 30, 2026, compared to $1.2 billion as of December 31, 2025.Research & Development (R&D) Expenses: R&D expenses were $95.1 million for the second quarter of 2026, compared to $101.8 million for the second quarter of 2025.General & Administrative (G&A) Expenses: G&A expenses were $31.9 million for the second quarter of 2026, compared to $26.9 million for the second quarter of 2025.Net Income (Loss): Net loss was $122.7 million, or $1.18 per share, for the second quarter of 2026, compared to net loss of $102.1 million, or $1.00 per share, for the second quarter of 2025. Cash Runway Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, funding the company through the anticipated launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304; our planned submission of a BLA for risto-cel; our expectations regarding the anticipated launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our expected presentations at upcoming medical conferences, including at the ERS Congress; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Contacts: Investors: Holly Manning Beam Therapeutics [email protected] Media: Josie Butler 1AB [email protected] Condensed Consolidated Balance Sheet Data (unaudited)(in thousands) June 30, 2026 December 31, 2025Cash, cash equivalents, and marketable securities$1,152,927 $1,245,210 Total assets 1,386,355 1,481,177 Total liabilities 318,913 242,819 Total stockholders’ equity 1,067,442 1,238,358 Condensed Consolidated Statement of Operations (unaudited)(in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025License and collaboration revenue$490 $8,466 $32,228 $15,936 Operating expenses: Research and development 95,096 101,758 199,620 200,574 General and administrative 31,947 26,859 66,376 54,799 Total operating expenses 127,043 128,617 265,996 255,373 Loss from operations (126,553) (120,151) (233,768) (239,437)Other income (expense): Change in fair value of derivative liabilities (4,200) 1,300 (1,700) 4,500 Change in fair value of non-controlling equity investments 338 4,415 354 2,334 Change in fair value of contingent consideration liabilities (205) (28) 309 (55)Gain on sale of equity method investment 455 — 455 — Interest and other income (expense), net 7,487 12,326 17,354 22,190 Total other income (expense) 3,875 18,013 16,772 28,969 Net loss$(122,678) $(102,138) $(216,996) $(210,468)Unrealized gain (loss) on marketable securities (1,119) (150) (3,300) (669)Comprehensive loss$(123,797) $(102,288) $(220,296) $(211,137)Net loss per common share, basic and diluted$(1.18) $(1.00) $(2.09) $(2.21)Weighted-average common shares outstanding, basic and diluted 104,325,436 101,995,184 103,797,276 95,023,977
	Saved 2026-07-20 19:57 1mo ago Published 2026-07-20 13:30 1mo ago	Cathie Wood dál nakupuje Beam Therapeutics Cathie Wood dál nakupuje Beam Therapeutics, jejíž pozice má hodnotu přes 300 milionů USD. Firma má 1,21 miliardy USD v hotovosti a několik klinických katalyzátorů. BEAM Beam Therapeutics	FMP Stock News	78
Original source text Cathie Wood of Ark Invest first bought shares of Beam Therapeutics (BEAM 4.36%), a biotech focused on precision genetic treatments, in 2020. She's continued to acquire shares since then, with her most recent purchases last week clocking in at around $4 million. Today, Wood's position in Beam is worth more than $300 million. That's not trivial, even for Wood. Of course, the question is: When it comes to Beam, should you follow her lead? I maintain that if you're comfortable with the risks of an early-stage biotech company, you should. Beam is taking a different approach to gene editing CRISPR gene editing involves cutting both strands of DNA before inserting or removing genetic material. Beam Therapeutics, however, uses a different technology called base editing. Instead of cutting DNA, base editing changes a single DNA letter directly. Think of it as correcting a typo in a document rather than deleting an entire sentence and rewriting it. The approach is designed to make genetic edits more precise. Image source: Getty Images. That technology becomes quite attractive when you consider that among more than 50,000 documented disease-causing genetic variants, roughly 60% are point mutations (a genetic alteration in which a single nucleotide in a DNA or RNA sequence is changed), making them potential targets for base editing. A maturing pipeline Beam now has several clinical programs that could create significant value over the next few years. Its most advanced liver-disease program, BEAM-302, is being developed for alpha-1 antitrypsin deficiency (an inherited disorder that leaves the liver and lungs vulnerable to progressive damage). Updated phase 1/2 data showed that a single treatment produced substantial increases in functional alpha-1 antitrypsin protein. The company has selected its optimal dose and expects to begin a global clinical trial in the second half of 2026. Beam is also developing ristoglogene autogetemcel (risto-cel), a potential one-time treatment for sickle cell disease. So far, clinical results have been encouraging, showing that the therapy can restore healthy function to red blood cells by increasing production of fetal hemoglobin. This is a key protein that helps prevent the painful complications caused by the disease. The company expects to file for approval from the U.S. Food and Drug Administration (FDA) by the end of 2026. If approved, risto-cel would become Beam's first commercial product, transforming it from a company focused solely on research into one capable of generating product revenue. Beam also plans to seek FDA approval to begin human testing of BEAM-304, a potential treatment for phenylketonuria (PKU). This rare inherited disorder prevents the body from properly breaking down the amino acid phenylalanine. Left untreated, the condition can lead to serious neurological problems. The company will also soon report its first clinical results for BEAM-301, a treatment for glycogen storage disease type Ia, a rare genetic disorder that prevents the liver from properly regulating blood sugar. While both programs are still in the early stages, they broaden Beam's pipeline and provide additional opportunities to create long-term value if the therapies prove successful. Plenty of cash One of the biggest risks for early-stage biotech companies is running out of cash before reaching meaningful clinical milestones. Beam appears to be in a stronger position than many of its peers. At the end of the first quarter, the company reported $1.21 billion in cash, cash equivalents, and marketable securities. Management believes that its cash, combined with a financing deal it has with specialty finance firm Sixth Street, is sufficient to fund operations through mid-2029. That gives Beam time to advance multiple clinical programs without immediately returning to capital markets for additional financing. Today's Change ( -4.36 %) $ -1.20 Current Price $ 26.33 Of course, none of this guarantees success. Beam Therapeutics reported a net loss of $94.3 million in Q1. Every major value driver still depends on successful clinical trials, regulatory approvals, and eventual commercialization. Failure in even one late-stage program could significantly affect the stock. Competition also continues to intensify. Companies including CRISPR Therapeutics and Verve Therapeutics (now a subsidiary of Eli Lilly) continue advancing their own gene-editing platforms. Beam's long-term success depends not only on proving that base editing works, but also that it offers meaningful advantages over competing technologies. Wood typically invests in companies capable of creating entirely new markets rather than simply improving existing ones. Beam fits that profile. The company has a differentiated gene-editing platform, multiple late-stage clinical catalysts over the next 18 months, more than $1.2 billion on its balance sheet, and enough capital to execute its development strategy well into 2029. That doesn't make Beam a low-risk investment. Clinical-stage biotechnology rarely is. But if you're willing to accept the volatility that comes with drug development, Beam Therapeutics appears to be one of the more compelling gene-editing companies on the market today.